{"organizations": [], "uuid": "76691e2802c4b0b5e1daa6444a7bc27feed63cb6", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-alder-biopharmaceuticals-new-data/brief-alder-biopharmaceuticals-new-data-demonstrated-eptinezumab-increased-migraine-free-intervals-in-patients-with-episodic-migraine-idUSFWN1S20YA", "country": "US", "domain_rank": 408, "title": "BRIEF-Alder Biopharmaceuticals - New Data Demonstrated Eptinezumab Increased Migraine-Free Intervals In Patients With Episodic Migraine", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-25T15:33:00.000+03:00", "replies_count": 0, "uuid": "76691e2802c4b0b5e1daa6444a7bc27feed63cb6"}, "author": "", "url": "https://www.reuters.com/article/brief-alder-biopharmaceuticals-new-data/brief-alder-biopharmaceuticals-new-data-demonstrated-eptinezumab-increased-migraine-free-intervals-in-patients-with-episodic-migraine-idUSFWN1S20YA", "ord_in_thread": 0, "title": "BRIEF-Alder Biopharmaceuticals - New Data Demonstrated Eptinezumab Increased Migraine-Free Intervals In Patients With Episodic Migraine", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "min read    alder biopharmaceuticals inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 25 (Reuters) - Alder Biopharmaceuticals Inc:\n* ALDER BIOPHARMACEUTICALSÂ® NEW DATA DEMONSTRATED EPTINEZUMAB INCREASED MIGRAINE-FREE INTERVALS (UP TO 32.5 DAYS) AND IMPROVED QUALITY-OF-LIFE OUTCOMES IN PATIENTS WITH EPISODIC MIGRAINE\n* ALDER BIOPHARMACEUTICALS INC - IN TRIAL, PATIENTS EXPERIENCED A SIGNIFICANT REDUCTION IN MIGRAINE DAYS AND IMPROVED QUALITY-OF-LIFE OUTCOMES\n* ALDER BIOPHARMA- IN POST HOC ANALYSIS, PATIENTS ACHIEVING A 75 PERCENT OR GREATER RESPONSE RATE HAD OVER AN 8-FOLD INCREASE IN DAYS BETWEEN MIGRAINES\n* ALDER BIOPHARMACEUTICALS INC - 29.7 PERCENT OF PATIENTS ACHIEVED A 75 PERCENT OR GREATER REDUCTION IN MIGRAINE DAYS FROM BASELINE\n* ALDER BIOPHARMACEUTICALS INC - OBSERVED SAFETY PROFILE FOR PROMISE 1, TO DATE, IS CONSISTENT WITH PREVIOUSLY REPORTED EPTINEZUMAB STUDIES Source text for Eikon: Further company coverage:\n ", "external_links": [], "published": "2018-04-25T15:33:00.000+03:00", "crawled": "2018-04-25T15:55:44.006+03:00", "highlightTitle": ""}